drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00250 | DB06674 | 10 | 908 | [
"DDInter475",
"DDInter837"
] | Dapsone | Golimumab | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
10,
24,
908
]
],
[
[
10,
63,
268
],
[
268,
24,
908
]
],
[
[
10,
24,
505
],
[
505,
63,
908
]
],
[
[
10,
24,
458
],
[
458,
24,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Diiodo... |
DB00543 | DB01166 | 87 | 477 | [
"DDInter82",
"DDInter379"
] | Amoxapine | Cilostazol | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
87,
24,
477
]
],
[
[
87,
6,
12523
],
[
12523,
45,
477
]
],
[
[
87,
21,
28658
],
[
28658,
60,
477
]
],
[
[
87,
23,
112
],
[
112,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Amoxapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Amoxapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Cilostazol (Compound)
Amoxapine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cilostazol (Compound)
Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronid... |
DB01200 | DB11730 | 469 | 351 | [
"DDInter243",
"DDInter1588"
] | Bromocriptine | Ribociclib | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
469,
24,
351
]
],
[
[
469,
24,
283
],
[
283,
62,
351
]
],
[
[
469,
40,
628
],
[
628,
24,
351
]
],
[
[
469,
63,
1324
],
[
1324,
2... | [
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Bromocriptine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that... |
DB00069 | DB00704 | 367 | 267 | [
"DDInter946",
"DDInter1263"
] | Interferon alfacon-1 | Naltrexone | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
367,
24,
267
]
],
[
[
367,
24,
522
],
[
522,
24,
267
]
],
[
[
367,
24,
850
],
[
850,
63,
267
]
],
[
[
367,
25,
72
],
[
72,
63,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlu... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00748 | DB00831 | 662 | 1,178 | [
"DDInter297",
"DDInter1866"
] | Carbinoxamine | Trifluoperazine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
662,
24,
1178
]
],
[
[
662,
63,
695
],
[
695,
40,
1178
]
],
[
[
662,
24,
146
],
[
146,
40,
1178
]
],
[
[
662,
24,
9
],
[
9,
1,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
]... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Trifluope... |
DB00787 | DB00980 | 387 | 969 | [
"DDInter25",
"DDInter1564"
] | Acyclovir | Ramelteon | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
387,
24,
969
]
],
[
[
387,
21,
28714
],
[
28714,
60,
969
]
],
[
[
387,
24,
1532
],
[
1532,
63,
969
]
],
[
[
387,
21,
28714
],
[
28714,... | [
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Acyclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by... | Acyclovir (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Ac... |
DB00424 | DB01233 | 19 | 1,311 | [
"DDInter896",
"DDInter1197"
] | Hyoscyamine | Metoclopramide | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
19,
24,
1311
]
],
[
[
19,
24,
1425
],
[
1425,
40,
1311
]
],
[
[
19,
6,
7992
],
[
7992,
45,
1311
]
],
[
[
19,
21,
28691
],
[
28691,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride (Compound) resembles Metoclopramide (Compound)
Hyoscyamine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Metoclopramide (Compound)
Hyoscyamine (Compound) causes Somnolence (Side Effect) and S... |
DB00230 | DB00792 | 784 | 832 | [
"DDInter1516",
"DDInter1878"
] | Pregabalin | Tripelennamine | Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evide... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
784,
24,
832
]
],
[
[
784,
24,
100
],
[
100,
63,
832
]
],
[
[
784,
24,
649
],
[
649,
1,
832
]
],
[
[
784,
24,
1594
],
[
1594,
24... | [
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],... | Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Clofeda... |
DB00489 | DB01377 | 17 | 1,283 | [
"DDInter1704",
"DDInter1119"
] | Sotalol | Magnesium oxide | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
17,
23,
1283
]
],
[
[
17,
24,
104
],
[
104,
23,
1283
]
],
[
[
17,
63,
999
],
[
999,
23,
1283
]
],
[
[
17,
25,
820
],
[
820,
23,
... | [
[
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and... |
DB01168 | DB01203 | 1,053 | 699 | [
"DDInter1526",
"DDInter1255"
] | Procarbazine | Nadolol | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
1053,
24,
699
]
],
[
[
1053,
24,
729
],
[
729,
1,
699
]
],
[
[
1053,
63,
887
],
[
887,
1,
699
]
],
[
[
1053,
21,
28882
],
[
28882,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Nadolol (Compound)
Procar... |
DB05773 | DB06779 | 1,047 | 365 | [
"DDInter1848",
"DDInter470"
] | Trastuzumab emtansine | Dalteparin | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
1047,
25,
365
]
],
[
[
1047,
63,
305
],
[
305,
24,
365
]
],
[
[
1047,
24,
1427
],
[
1427,
63,
365
]
],
[
[
1047,
24,
643
],
[
643,
... | [
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escheri... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Trastuzumab emtansine may cause a moderate interaction that cou... |
DB00620 | DB08912 | 175 | 1,040 | [
"DDInter1855",
"DDInter462"
] | Triamcinolone | Dabrafenib | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
175,
24,
1040
]
],
[
[
175,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
175,
7,
2969
],
[
2969,
46,
1040
]
],
[
[
175,
18,
2097
],
[
2097,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Triamcinolone (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound)
Triamcinolone (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Triam... |
DB00867 | DB06699 | 1,052 | 774 | [
"DDInter1606",
"DDInter493"
] | Ritodrine | Degarelix | Adrenergic beta-agonist used to control premature labor. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1052,
24,
774
]
],
[
[
1052,
63,
521
],
[
521,
1,
774
]
],
[
[
1052,
63,
888
],
[
888,
24,
774
]
],
[
[
1052,
24,
484
],
[
484,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacer... |
DB00524 | DB09156 | 811 | 777 | [
"DDInter1199",
"DDInter964"
] | Metolazone | Iopromide | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
811,
24,
777
]
],
[
[
811,
63,
1648
],
[
1648,
24,
777
]
],
[
[
811,
1,
359
],
[
359,
24,
777
]
],
[
[
811,
40,
1014
],
[
1014,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction t... |
DB06810 | DB09498 | 397 | 810 | [
"DDInter1484",
"DDInter1715"
] | Plicamycin | Strontium chloride Sr-89 | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
397,
24,
810
]
],
[
[
397,
63,
597
],
[
597,
24,
810
]
],
[
[
397,
25,
503
],
[
503,
63,
810
]
],
[
[
397,
24,
1362
],
[
1362,
2... | [
[
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenic... | Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Plicamycin may lead to a major life threatening interaction when taken with Zanubrutinib... |
DB00405 | DB00477 | 128 | 216 | [
"DDInter517",
"DDInter363"
] | Dexbrompheniramine | Chlorpromazine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
128,
24,
216
]
],
[
[
128,
24,
1178
],
[
1178,
1,
216
]
],
[
[
128,
63,
902
],
[
902,
40,
216
]
],
[
[
128,
24,
1216
],
[
1216,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluo... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resemb... |
DB00363 | DB00491 | 695 | 127 | [
"DDInter419",
"DDInter1217"
] | Clozapine | Miglitol | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Moderate | 1 | [
[
[
695,
24,
127
]
],
[
[
695,
25,
1491
],
[
1491,
63,
127
]
],
[
[
695,
24,
104
],
[
104,
63,
127
]
],
[
[
695,
1,
623
],
[
623,
63... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",... | Clozapine may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Miglitol
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may caus... |
DB00556 | DB09268 | 1,262 | 1,662 | [
"DDInter1429",
"DDInter1464"
] | Perflutren | Picosulfuric acid | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1262,
24,
1662
]
],
[
[
1262,
24,
484
],
[
484,
63,
1662
]
],
[
[
1262,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
1262,
24,
1491
],
[
1491... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
... | Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Perflutren may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantin... |
DB00374 | DB01089 | 1,061 | 1,340 | [
"DDInter1852",
"DDInter502"
] | Treprostinil | Deserpidine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Moderate | 1 | [
[
[
1061,
24,
1340
]
],
[
[
1061,
63,
1245
],
[
1245,
40,
1340
]
],
[
[
1061,
24,
1445
],
[
1445,
24,
1340
]
],
[
[
1061,
24,
1455
],
[
14... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interacti... |
DB00635 | DB12332 | 1,573 | 1,619 | [
"DDInter1515",
"DDInter1626"
] | Prednisone | Rucaparib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1573,
24,
1619
]
],
[
[
1573,
23,
307
],
[
307,
23,
1619
]
],
[
[
1573,
24,
259
],
[
259,
24,
1619
]
],
[
[
1573,
24,
151
],
[
151,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Prednisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept ma... |
DB00046 | DB00279 | 1,179 | 1,152 | [
"DDInter940",
"DDInter1074"
] | Insulin lispro | Liothyronine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Moderate | 1 | [
[
[
1179,
24,
1152
]
],
[
[
1179,
24,
624
],
[
624,
40,
1152
]
],
[
[
1179,
24,
1523
],
[
1523,
62,
1152
]
],
[
[
1179,
24,
88
],
[
88,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Liotrix and Liotrix (Compound) resembles Liothyronine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a minor interaction that can li... |
DB00812 | DB05676 | 998 | 1,513 | [
"DDInter1451",
"DDInter111"
] | Phenylbutazone | Apremilast | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Moderate | 1 | [
[
[
998,
24,
1513
]
],
[
[
998,
40,
307
],
[
307,
23,
1513
]
],
[
[
998,
25,
1421
],
[
1421,
63,
1513
]
],
[
[
998,
62,
1101
],
[
1101,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a m... | Phenylbutazone (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Phenylbutazone may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate... |
DB04844 | DB06691 | 843 | 849 | [
"DDInter1778",
"DDInter1155"
] | Tetrabenazine | Mepyramine | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
843,
24,
849
]
],
[
[
843,
63,
1594
],
[
1594,
24,
849
]
],
[
[
843,
6,
12523
],
[
12523,
45,
849
]
],
[
[
843,
24,
407
],
[
407,
... | [
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Tetrabenazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Tetrabenazin... |
DB09075 | DB12364 | 498 | 1,421 | [
"DDInter621",
"DDInter200"
] | Edoxaban | Betrixaban | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
498,
25,
1421
]
],
[
[
498,
23,
297
],
[
297,
23,
1421
]
],
[
[
498,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
498,
24,
992
],
[
992,
... | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Edoxaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} ma... | Edoxaban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Edoxaban may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor i... |
DB10583 | DB12498 | 949 | 76 | [
"DDInter415",
"DDInter1238"
] | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Mogamulizumab | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Moderate | 1 | [
[
[
949,
24,
76
]
],
[
[
949,
63,
1531
],
[
1531,
24,
76
]
],
[
[
949,
24,
738
],
[
738,
24,
76
]
],
[
[
949,
24,
676
],
[
676,
64,
... | [
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moder... | Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Clostridium tetani toxoid antigen (formaldehyde inactivat... |
DB01064 | DB05812 | 1,148 | 1,374 | [
"DDInter987",
"DDInter8"
] | Isoprenaline | Abiraterone | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1148,
24,
1374
]
],
[
[
1148,
21,
28695
],
[
28695,
60,
1374
]
],
[
[
1148,
24,
1399
],
[
1399,
63,
1374
]
],
[
[
1148,
63,
109
],
[
1... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is c... | Isoprenaline (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Abiraterone (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when t... |
DB00262 | DB12674 | 552 | 975 | [
"DDInter302",
"DDInter1105"
] | Carmustine | Lurbinectedin | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
552,
24,
975
]
],
[
[
552,
24,
1613
],
[
1613,
24,
975
]
],
[
[
552,
63,
1560
],
[
1560,
24,
975
]
],
[
[
552,
35,
37
],
[
37,
2... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Carmustine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01024 | DB01627 | 1,096 | 1,208 | [
"DDInter1252",
"DDInter1071"
] | Mycophenolic acid | Lincomycin | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin re... | Moderate | 1 | [
[
[
1096,
24,
1208
]
],
[
[
1096,
24,
568
],
[
568,
40,
1208
]
],
[
[
1096,
18,
4675
],
[
4675,
57,
1208
]
],
[
[
1096,
21,
28826
],
[
288... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lincomycin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin and Clindamycin (Compound) resembles Lincomycin (Compound)
Mycophenolic acid (Compound) downregulates PLOD3 (Gene) and PLOD3 (Gene) is downregulated by Lincomycin (Compound)
Mycophenolic acid (Compound) causes ... |
DB01208 | DB06699 | 945 | 774 | [
"DDInter1705",
"DDInter493"
] | Sparfloxacin | Degarelix | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
945,
25,
774
]
],
[
[
945,
64,
521
],
[
521,
1,
774
]
],
[
[
945,
21,
29232
],
[
29232,
60,
774
]
],
[
[
945,
62,
112
],
[
112,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} ... | Sparfloxacin may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Sparfloxacin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Sparfloxacin may cause a minor interaction that can limit c... |
DB00023 | DB00722 | 305 | 743 | [
"DDInter127",
"DDInter1079"
] | Asparaginase Escherichia coli | Lisinopril | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
305,
24,
743
]
],
[
[
305,
24,
610
],
[
610,
40,
743
]
],
[
[
305,
24,
1638
],
[
1638,
1,
743
]
],
[
[
305,
24,
5
],
[
5,
62,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Co... |
DB00845 | DB06603 | 1,490 | 39 | [
"DDInter406",
"DDInter1387"
] | Clofazimine | Panobinostat | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1490,
25,
39
]
],
[
[
1490,
23,
112
],
[
112,
23,
39
]
],
[
[
1490,
24,
455
],
[
455,
24,
39
]
],
[
[
1490,
24,
720
],
[
720,
63... | [
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and ... |
DB00352 | DB04854 | 482 | 1,291 | [
"DDInter1814",
"DDInter713"
] | Tioguanine | Febuxostat | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult pat... | Moderate | 1 | [
[
[
482,
24,
1291
]
],
[
[
482,
24,
372
],
[
372,
24,
1291
]
],
[
[
482,
24,
384
],
[
384,
63,
1291
]
],
[
[
482,
63,
1560
],
[
1560,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Febuxostat"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Febuxostat
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idel... |
DB00480 | DB00704 | 1,668 | 267 | [
"DDInter1035",
"DDInter1263"
] | Lenalidomide | Naltrexone | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1668,
24,
267
]
],
[
[
1668,
6,
4973
],
[
4973,
45,
267
]
],
[
[
1668,
7,
4830
],
[
4830,
46,
267
]
],
[
[
1668,
18,
20113
],
[
20113,... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Lenalidomide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Lenalidomide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naltrexone (Compound)
Lenalidomide (Compound) upregulates TGFBR2 (Gene) and TGFBR2 (Gene) is upregulated by Naltrexone (Compound)
Lenalidomide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Naltrexone (Compound)
Lenalidomi... |
DB01087 | DB06702 | 1,520 | 573 | [
"DDInter1520",
"DDInter731"
] | Primaquine | Fesoterodine | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1520,
24,
573
]
],
[
[
1520,
62,
211
],
[
211,
1,
573
]
],
[
[
1520,
64,
494
],
[
494,
1,
573
]
],
[
[
1520,
6,
12523
],
[
12523,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
],
[
... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Primaquine may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Compound)
Primaqu... |
DB00241 | DB11130 | 288 | 407 | [
"DDInter257",
"DDInter1344"
] | Butalbital | Opium | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
288,
24,
407
]
],
[
[
288,
24,
662
],
[
662,
24,
407
]
],
[
[
288,
40,
1023
],
[
1023,
24,
407
]
],
[
[
288,
63,
1648
],
[
1648,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction tha... |
DB01017 | DB01602 | 1,669 | 339 | [
"DDInter1224",
"DDInter159"
] | Minocycline | Bacampicillin | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal ac... | Moderate | 1 | [
[
[
1669,
24,
339
]
],
[
[
1669,
63,
703
],
[
703,
1,
339
]
],
[
[
1669,
24,
950
],
[
950,
40,
339
]
],
[
[
1669,
63,
916
],
[
916,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacampicillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbenicillin"
],
... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Carbenicillin and Carbenicillin (Compound) resembles Bacampicillin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Cloxacillin and Cloxacillin (Compound) resembles Bacampici... |
DB00490 | DB12010 | 946 | 214 | [
"DDInter254",
"DDInter785"
] | Buspirone | Fostamatinib | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
946,
24,
214
]
],
[
[
946,
24,
723
],
[
723,
24,
214
]
],
[
[
946,
63,
600
],
[
600,
24,
214
]
],
[
[
946,
25,
222
],
[
222,
24,... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluco... |
DB00454 | DB08895 | 1,349 | 976 | [
"DDInter1150",
"DDInter1825"
] | Meperidine | Tofacitinib | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1349,
24,
976
]
],
[
[
1349,
24,
214
],
[
214,
63,
976
]
],
[
[
1349,
64,
475
],
[
475,
24,
976
]
],
[
[
1349,
40,
411
],
[
411,
... | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[... | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Meperidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause... |
DB00448 | DB01066 | 1,215 | 1,462 | [
"DDInter1022",
"DDInter316"
] | Lansoprazole | Cefditoren | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Moderate | 1 | [
[
[
1215,
24,
1462
]
],
[
[
1215,
24,
665
],
[
665,
40,
1462
]
],
[
[
1215,
40,
837
],
[
837,
24,
1462
]
],
[
[
1215,
24,
126
],
[
126,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound)
Lansoprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cef... |
DB06603 | DB10429 | 39 | 200 | [
"DDInter1387",
"DDInter282"
] | Panobinostat | Candida albicans | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
39,
24,
200
]
],
[
[
39,
63,
1683
],
[
1683,
24,
200
]
],
[
[
39,
25,
976
],
[
976,
24,
200
]
],
[
[
39,
64,
51
],
[
51,
24,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Panobinostat may lead to a major life threatening interaction when taken with Tofacitinib and Tofaciti... |
DB00238 | DB09049 | 188 | 1,135 | [
"DDInter1285",
"DDInter1261"
] | Nevirapine | Naloxegol | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Moderate | 1 | [
[
[
188,
24,
1135
]
],
[
[
188,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
188,
24,
971
],
[
971,
62,
1135
]
],
[
[
188,
24,
1424
],
[
1424,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
... | Nevirapine may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a... |
DB00850 | DB00981 | 1,630 | 1,528 | [
"DDInter1432",
"DDInter1463"
] | Perphenazine | Physostigmine (ophthalmic) | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Moderate | 1 | [
[
[
1630,
24,
1528
]
],
[
[
1630,
21,
28751
],
[
28751,
60,
1528
]
],
[
[
1630,
1,
508
],
[
508,
24,
1528
]
],
[
[
1630,
24,
1511
],
[
151... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Perphenazine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Perphenazine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Physostigmine (Compound)
Perphenazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate ... |
DB01309 | DB06791 | 1,254 | 1,446 | [
"DDInter933",
"DDInter1021"
] | Insulin glulisine | Lanreotide | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
1254,
24,
1446
]
],
[
[
1254,
24,
154
],
[
154,
63,
1446
]
],
[
[
1254,
63,
887
],
[
887,
24,
1446
]
],
[
[
1254,
24,
549
],
[
549,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Pindolo... |
DB00370 | DB11978 | 1,251 | 124 | [
"DDInter1230",
"DDInter822"
] | Mirtazapine | Glasdegib | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1251,
24,
124
]
],
[
[
1251,
23,
112
],
[
112,
23,
124
]
],
[
[
1251,
63,
475
],
[
475,
24,
124
]
],
[
[
1251,
24,
79
],
[
79,
2... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Mirtazapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morph... |
DB01058 | DB11652 | 978 | 1,155 | [
"DDInter1510",
"DDInter1891"
] | Praziquantel | Tucatinib | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
978,
24,
1155
]
],
[
[
978,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
978,
24,
1320
],
[
1320,
63,
1155
]
],
[
[
978,
24,
1094
],
[
1094,
... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagoli... |
DB00390 | DB01611 | 1,252 | 1,487 | [
"DDInter554",
"DDInter893"
] | Digoxin | Hydroxychloroquine | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1252,
24,
1487
]
],
[
[
1252,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
1252,
24,
663
],
[
663,
23,
1487
]
],
[
[
1252,
23,
1283
],
[
12... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caus... | Digoxin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Hydro... |
DB00220 | DB06589 | 798 | 1,250 | [
"DDInter1276",
"DDInter1400"
] | Nelfinavir | Pazopanib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
798,
25,
1250
]
],
[
[
798,
6,
15333
],
[
15333,
45,
1250
]
],
[
[
798,
7,
8386
],
[
8386,
46,
1250
]
],
[
[
798,
7,
9384
],
[
9384,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopa... | Nelfinavir (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Pazopanib (Compound)
Nelfinavir (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Pazopanib (Compound)
Nelfinavir (Compound) upregulates TRIB3 (Gene) and TRIB3 (Gene) is downregulated by Pazopanib (Compound)
Nelfinavir (Com... |
DB00188 | DB00559 | 168 | 152 | [
"DDInter222",
"DDInter223"
] | Bortezomib | Bosentan | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Minor | 0 | [
[
[
168,
23,
152
]
],
[
[
168,
6,
6017
],
[
6017,
45,
152
]
],
[
[
168,
33,
5795
],
[
5795,
57,
152
]
],
[
[
168,
21,
29402
],
[
29402,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosentan"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Bortezomib (Compound) binds PSMB8 (Gene) and Bortezomib (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is downregulated by Bosentan (Compound)
Bortezomib (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobi... |
DB12035 | DB12141 | 943 | 971 | [
"DDInter1641",
"DDInter817"
] | Sarecycline | Gilteritinib | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007. After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
943,
24,
971
]
],
[
[
943,
62,
1135
],
[
1135,
23,
971
]
],
[
[
943,
63,
1181
],
[
1181,
24,
971
]
],
[
[
943,
24,
1421
],
[
1421,
... | [
[
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Sarecycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Sarecycline may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfena... |
DB00022 | DB12839 | 268 | 919 | [
"DDInter1408",
"DDInter1411"
] | Peginterferon alfa-2b | Pegvaliase | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Pegvaliase is a recombinant phenylalanine ammonia lyase (PAL) enzyme derived from _Anabaena variabilis_ that converts phenylalanine to ammonia and _trans_-cinnamic acid . Both the U.S. Food and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients wit... | Moderate | 1 | [
[
[
268,
24,
919
]
],
[
[
268,
63,
1257
],
[
1257,
24,
919
]
],
[
[
268,
24,
934
],
[
934,
24,
919
]
],
[
[
268,
63,
1257
],
[
1257,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegvaliase"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfi... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Pegvaliase
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when take... |
DB00675 | DB01611 | 888 | 1,487 | [
"DDInter1744",
"DDInter893"
] | Tamoxifen | Hydroxychloroquine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
888,
25,
1487
]
],
[
[
888,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
888,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
888,
21,
28658
],
[
2865... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Prim... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Tamoxifen (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Tamoxifen (Compound... |
DB00238 | DB01229 | 188 | 973 | [
"DDInter1285",
"DDInter1377"
] | Nevirapine | Paclitaxel | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
188,
24,
973
]
],
[
[
188,
24,
310
],
[
310,
63,
973
]
],
[
[
188,
6,
7524
],
[
7524,
45,
973
]
],
[
[
188,
21,
29267
],
[
29267,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Nevirapine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Nevirapine (Comp... |
DB00704 | DB06626 | 267 | 263 | [
"DDInter1263",
"DDInter147"
] | Naltrexone | Axitinib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
267,
24,
263
]
],
[
[
267,
63,
322
],
[
322,
24,
263
]
],
[
[
267,
24,
392
],
[
392,
24,
263
]
],
[
[
267,
24,
1593
],
[
1593,
6... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib... |
DB00446 | DB01413 | 597 | 1,403 | [
"DDInter351",
"DDInter317"
] | Chloramphenicol | Cefepime | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics.[A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections ca... | Moderate | 1 | [
[
[
597,
24,
1403
]
],
[
[
597,
24,
1462
],
[
1462,
1,
1403
]
],
[
[
597,
24,
1024
],
[
1024,
40,
1403
]
],
[
[
597,
63,
149
],
[
149,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
],
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Cefepime (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefpodoxime and Cefpodoxime (Compound) resembles Cefepime (Co... |
DB00001 | DB00013 | 1,578 | 1,255 | [
"DDInter1037",
"DDInter1905"
] | Lepirudin | Urokinase | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Major | 2 | [
[
[
1578,
25,
1255
]
],
[
[
1578,
23,
539
],
[
539,
62,
1255
]
],
[
[
1578,
24,
578
],
[
578,
63,
1255
]
],
[
[
1578,
25,
1347
],
[
1347,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Urokinase"
]
],
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Lepirudin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Urokinase
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may ca... |
DB00191 | DB06706 | 73 | 468 | [
"DDInter1447",
"DDInter985"
] | Phentermine | Isometheptene | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
73,
24,
468
]
],
[
[
73,
24,
1000
],
[
1000,
24,
468
]
],
[
[
73,
24,
320
],
[
320,
63,
468
]
],
[
[
73,
25,
1100
],
[
1100,
24,... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanadrel"
],
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine a... |
DB00816 | DB01591 | 1,674 | 667 | [
"DDInter1346",
"DDInter1696"
] | Orciprenaline | Solifenacin | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1674,
24,
667
]
],
[
[
1674,
21,
29462
],
[
29462,
60,
667
]
],
[
[
1674,
24,
774
],
[
774,
63,
667
]
],
[
[
1674,
63,
1324
],
[
1324,... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Influenza"
],
[
"Influenza",
"{u} (Side Effect) ... | Orciprenaline (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Solifenacin (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with So... |
DB00612 | DB00860 | 1,121 | 891 | [
"DDInter216",
"DDInter1513"
] | Bisoprolol | Prednisolone | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1121,
24,
891
]
],
[
[
1121,
24,
175
],
[
175,
40,
891
]
],
[
[
1121,
24,
167
],
[
167,
1,
891
]
],
[
[
1121,
63,
251
],
[
251,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predni... |
DB06704 | DB14409 | 247 | 1,129 | [
"DDInter952",
"DDInter867"
] | Iobenguane (I-131) | Human adenovirus e serotype 4 strain cl-68578 antigen | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
247,
24,
1129
]
],
[
[
247,
7,
6952
],
[
6952,
46,
77
],
[
77,
24,
1129
]
],
[
[
247,
18,
7359
],
[
7359,
57,
147
],
[
147,
24,
... | [
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Iobenguane",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1... | Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Iobenguane (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate... |
DB00188 | DB00582 | 168 | 1,622 | [
"DDInter222",
"DDInter1946"
] | Bortezomib | Voriconazole | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Moderate | 1 | [
[
[
168,
24,
1622
]
],
[
[
168,
6,
8374
],
[
8374,
45,
1622
]
],
[
[
168,
21,
28957
],
[
28957,
60,
1622
]
],
[
[
168,
24,
112
],
[
112,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Voriconazole (Compound)
Bortezomib (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Voriconazole (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole... |
DB00443 | DB10675 | 251 | 961 | [
"DDInter195",
"DDInter1065"
] | Betamethasone | Licorice | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Licorice allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
251,
24,
961
]
],
[
[
251,
40,
870
],
[
870,
24,
961
]
],
[
[
251,
1,
891
],
[
891,
24,
961
]
],
[
[
251,
24,
1231
],
[
1231,
24... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may c... | Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when take... |
DB00526 | DB11718 | 1,555 | 927 | [
"DDInter1355",
"DDInter640"
] | Oxaliplatin | Encorafenib | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1555,
24,
927
]
],
[
[
1555,
24,
112
],
[
112,
23,
927
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
927
]
],
[
[
1555,
24,
720
],
[
720,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole... |
DB00802 | DB01246 | 1,322 | 820 | [
"DDInter43",
"DDInter45"
] | Alfentanil | Alimemazine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1322,
24,
820
]
],
[
[
1322,
24,
104
],
[
104,
40,
820
]
],
[
[
1322,
24,
401
],
[
401,
24,
820
]
],
[
[
1322,
24,
649
],
[
649,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction t... |
DB08912 | DB11581 | 1,040 | 1,456 | [
"DDInter462",
"DDInter1926"
] | Dabrafenib | Venetoclax | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
1040,
25,
1456
]
],
[
[
1040,
24,
1135
],
[
1135,
23,
1456
]
],
[
[
1040,
25,
241
],
[
241,
63,
1456
]
],
[
[
1040,
23,
230
],
[
230,
... | [
[
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Dabrafenib may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may cause a ... |
DB00594 | DB11113 | 863 | 657 | [
"DDInter68",
"DDInter307"
] | Amiloride | Castor oil | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
863,
24,
657
]
],
[
[
863,
24,
891
],
[
891,
24,
657
]
],
[
[
863,
24,
1019
],
[
1019,
63,
657
]
],
[
[
863,
63,
355
],
[
355,
2... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Def... |
DB00159 | DB00975 | 940 | 1,317 | [
"DDInter903",
"DDInter573"
] | Icosapent | Dipyridamole | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
940,
24,
1317
]
],
[
[
940,
21,
28778
],
[
28778,
60,
1317
]
],
[
[
940,
24,
714
],
[
714,
63,
1317
]
],
[
[
940,
63,
1167
],
[
1167,
... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Icosapent",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Si... | Icosapent (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Dipyridamole (Compound)
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when take... |
DB00281 | DB00976 | 608 | 1,056 | [
"DDInter1066",
"DDInter1758"
] | Lidocaine | Telithromycin | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Moderate | 1 | [
[
[
608,
24,
1056
]
],
[
[
608,
6,
7950
],
[
7950,
45,
1056
]
],
[
[
608,
21,
28681
],
[
28681,
60,
1056
]
],
[
[
608,
23,
1220
],
[
1220,... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)"... | Lidocaine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Telithromycin (Compound)
Lidocaine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Telithromycin (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dexa... |
DB00745 | DB00773 | 307 | 896 | [
"DDInter1236",
"DDInter702"
] | Modafinil | Etoposide | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Minor | 0 | [
[
[
307,
23,
896
]
],
[
[
307,
6,
7524
],
[
7524,
45,
896
]
],
[
[
307,
18,
10375
],
[
10375,
57,
896
]
],
[
[
307,
21,
28681
],
[
28681,
... | [
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Modafinil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Etoposide (Compound)
Modafinil (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Etoposide (Compound)
Modafinil (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Co... |
DB00353 | DB01017 | 588 | 1,669 | [
"DDInter1187",
"DDInter1224"
] | Methylergometrine | Minocycline | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
588,
24,
1669
]
],
[
[
588,
24,
1572
],
[
1572,
1,
1669
]
],
[
[
588,
63,
964
],
[
964,
1,
1669
]
],
[
[
588,
24,
1545
],
[
1545,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycli... | Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembl... |
DB01097 | DB11703 | 1,377 | 405 | [
"DDInter1033",
"DDInter9"
] | Leflunomide | Acalabrutinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1377,
25,
405
]
],
[
[
1377,
64,
1324
],
[
1324,
24,
405
]
],
[
[
1377,
24,
248
],
[
248,
24,
405
]
],
[
[
1377,
25,
901
],
[
901,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
... | Leflunomide may lead to a major life threatening interaction when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganci... |
DB00749 | DB08890 | 59 | 16 | [
"DDInter699",
"DDInter1069"
] | Etodolac | Linaclotide | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Minor | 0 | [
[
[
59,
23,
16
]
],
[
[
59,
63,
1314
],
[
1314,
40,
16
]
],
[
[
59,
63,
1512
],
[
1512,
23,
16
]
],
[
[
59,
24,
848
],
[
848,
23,
... | [
[
[
"Etodolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Linaclotide (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can lim... |
DB00692 | DB08815 | 274 | 154 | [
"DDInter1448",
"DDInter1104"
] | Phentolamine | Lurasidone | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
274,
24,
154
]
],
[
[
274,
6,
5299
],
[
5299,
45,
154
]
],
[
[
274,
21,
29118
],
[
29118,
60,
154
]
],
[
[
274,
24,
401
],
[
401,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Phentolamine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2C"
],
[
"ADRA2C",
"{u} (Gene) is bound by {v} (Compoun... | Phentolamine (Compound) binds ADRA2C (Gene) and ADRA2C (Gene) is bound by Lurasidone (Compound)
Phentolamine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Lurasidone (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Promethaz... |
DB00490 | DB00692 | 946 | 274 | [
"DDInter254",
"DDInter1448"
] | Buspirone | Phentolamine | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Moderate | 1 | [
[
[
946,
24,
274
]
],
[
[
946,
21,
29118
],
[
29118,
60,
274
]
],
[
[
946,
63,
530
],
[
530,
24,
274
]
],
[
[
946,
24,
104
],
[
104,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Buspirone",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is ... | Buspirone (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Phentolamine (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phe... |
DB00938 | DB11915 | 455 | 1,293 | [
"DDInter1635",
"DDInter1909"
] | Salmeterol | Valbenazine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
455,
24,
1293
]
],
[
[
455,
63,
521
],
[
521,
24,
1293
]
],
[
[
455,
24,
401
],
[
401,
24,
1293
]
],
[
[
455,
24,
159
],
[
159,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prome... |
DB01259 | DB06603 | 392 | 39 | [
"DDInter1024",
"DDInter1387"
] | Lapatinib | Panobinostat | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
392,
25,
39
]
],
[
[
392,
62,
1247
],
[
1247,
23,
39
]
],
[
[
392,
63,
211
],
[
211,
23,
39
]
],
[
[
392,
63,
912
],
[
912,
24,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfam... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine a... |
DB00903 | DB11827 | 1,680 | 433 | [
"DDInter686",
"DDInter669"
] | Etacrynic acid | Ertugliflozin | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1680,
24,
433
]
],
[
[
1680,
24,
959
],
[
959,
24,
433
]
],
[
[
1680,
63,
251
],
[
251,
24,
433
]
],
[
[
1680,
24,
1019
],
[
1019,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Betamethason... |
DB00889 | DB09104 | 1,133 | 286 | [
"DDInter840",
"DDInter1118"
] | Granisetron | Magnesium hydroxide | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1133,
24,
286
]
],
[
[
1133,
24,
820
],
[
820,
23,
286
]
],
[
[
1133,
64,
109
],
[
109,
23,
286
]
],
[
[
1133,
63,
355
],
[
355,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Granisetron may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine... |
DB04896 | DB06441 | 901 | 936 | [
"DDInter1220",
"DDInter283"
] | Milnacipran | Cangrelor | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Moderate | 1 | [
[
[
901,
24,
936
]
],
[
[
901,
63,
477
],
[
477,
24,
936
]
],
[
[
901,
40,
41
],
[
41,
63,
936
]
],
[
[
901,
64,
222
],
[
222,
24,
... | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
... | Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Milnacipran (Compound) resembles Levomilnacipran (Compound) and Levo
Milnacipran may lead to a major life threat... |
DB00372 | DB09128 | 999 | 1,241 | [
"DDInter1793",
"DDInter231"
] | Thiethylperazine | Brexpiprazole | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
999,
24,
1241
]
],
[
[
999,
24,
549
],
[
549,
24,
1241
]
],
[
[
999,
63,
1647
],
[
1647,
24,
1241
]
],
[
[
999,
24,
1296
],
[
1296,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozi... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01362 | DB06700 | 497 | 643 | [
"DDInter960",
"DDInter511"
] | Iohexol | Desvenlafaxine | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Major | 2 | [
[
[
497,
25,
643
]
],
[
[
497,
64,
1100
],
[
1100,
1,
643
]
],
[
[
497,
21,
28809
],
[
28809,
60,
643
]
],
[
[
497,
24,
1574
],
[
1574,
... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (... | Iohexol may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Iohexol (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Desvenlafaxine (Compound)
Iohexol may cause a moderate interaction that could exa... |
DB00222 | DB00574 | 245 | 121 | [
"DDInter825",
"DDInter717"
] | Glimepiride | Fenfluramine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
245,
24,
121
]
],
[
[
245,
24,
1144
],
[
1144,
63,
121
]
],
[
[
245,
24,
24
],
[
24,
24,
121
]
],
[
[
245,
23,
1347
],
[
1347,
6... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and To... |
DB01238 | DB08881 | 673 | 868 | [
"DDInter118",
"DDInter1925"
] | Aripiprazole | Vemurafenib | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
673,
24,
868
]
],
[
[
673,
6,
8374
],
[
8374,
45,
868
]
],
[
[
673,
7,
7153
],
[
7153,
46,
868
]
],
[
[
673,
18,
1918
],
[
1918,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Aripiprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Aripiprazole (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Vemurafenib (Compound)
Aripiprazole (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Vemurafenib (Compound)
Aripipraz... |
DB08880 | DB08885 | 1,510 | 363 | [
"DDInter1771",
"DDInter33"
] | Teriflunomide | Aflibercept | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Major | 2 | [
[
[
1510,
25,
363
]
],
[
[
1510,
64,
1531
],
[
1531,
24,
363
]
],
[
[
1510,
24,
151
],
[
151,
63,
363
]
],
[
[
1510,
25,
384
],
[
384,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aflibercept"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
... | Teriflunomide may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/Califor... |
DB00346 | DB01069 | 472 | 401 | [
"DDInter44",
"DDInter1533"
] | Alfuzosin | Promethazine | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
472,
24,
401
]
],
[
[
472,
24,
1264
],
[
1264,
63,
401
]
],
[
[
472,
24,
104
],
[
104,
24,
401
]
],
[
[
472,
6,
5214
],
[
5214,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazi... |
DB01259 | DB09020 | 392 | 28 | [
"DDInter1024",
"DDInter212"
] | Lapatinib | Bisacodyl | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
392,
24,
28
]
],
[
[
392,
18,
20113
],
[
20113,
46,
28
]
],
[
[
392,
7,
18008
],
[
18008,
46,
28
]
],
[
[
392,
7,
10643
],
[
10643,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Lapatinib",
"{u} (Compound) downregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is upregulated by {v} (Comp... | Lapatinib (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Bisacodyl (Compound)
Lapatinib (Compound) upregulates BAMBI (Gene) and BAMBI (Gene) is upregulated by Bisacodyl (Compound)
Lapatinib (Compound) upregulates EAPP (Gene) and EAPP (Gene) is downregulated by Bisacodyl (Compound)
Lapatinib (Com... |
DB06288 | DB08865 | 607 | 1,593 | [
"DDInter77",
"DDInter448"
] | Amisulpride | Crizotinib | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
607,
25,
1593
]
],
[
[
607,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
607,
24,
286
],
[
286,
63,
1593
]
],
[
[
607,
63,
455
],
[
455,
... | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Amisulpride",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compou... | Amisulpride (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when ta... |
DB00222 | DB00881 | 245 | 954 | [
"DDInter825",
"DDInter1554"
] | Glimepiride | Quinapril | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
245,
24,
954
]
],
[
[
245,
24,
1638
],
[
1638,
1,
954
]
],
[
[
245,
24,
1523
],
[
1523,
40,
954
]
],
[
[
245,
21,
28828
],
[
28828,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Quinapril (Compound... |
DB00317 | DB00496 | 883 | 194 | [
"DDInter810",
"DDInter480"
] | Gefitinib | Darifenacin | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Moderate | 1 | [
[
[
883,
24,
194
]
],
[
[
883,
6,
8374
],
[
8374,
45,
194
]
],
[
[
883,
7,
2759
],
[
2759,
46,
194
]
],
[
[
883,
18,
9429
],
[
9429,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Darifenacin (Compound)
Gefitinib (Compound) upregulates CEBPA (Gene) and CEBPA (Gene) is upregulated by Darifenacin (Compound)
Gefitinib (Compound) downregulates CNDP2 (Gene) and CNDP2 (Gene) is downregulated by Darifenacin (Compound)
Gefitinib (Com... |
DB00631 | DB01030 | 372 | 869 | [
"DDInter405",
"DDInter1835"
] | Clofarabine | Topotecan | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
372,
24,
869
]
],
[
[
372,
6,
17404
],
[
17404,
45,
869
]
],
[
[
372,
7,
1933
],
[
1933,
46,
869
]
],
[
[
372,
18,
7912
],
[
7912,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Clofarabine",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Clofarabine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Topotecan (Compound)
Clofarabine (Compound) upregulates TNFAIP3 (Gene) and TNFAIP3 (Gene) is upregulated by Topotecan (Compound)
Clofarabine (Compound) downregulates CCNF (Gene) and CCNF (Gene) is downregulated by Topotecan (Compound)
Clofarabine (C... |
DB00877 | DB12147 | 629 | 241 | [
"DDInter1678",
"DDInter661"
] | Sirolimus | Erdafitinib | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Moderate | 1 | [
[
[
629,
24,
241
]
],
[
[
629,
24,
170
],
[
170,
24,
241
]
],
[
[
629,
25,
384
],
[
384,
24,
241
]
],
[
[
629,
24,
982
],
[
982,
63,... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Sirolimus may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause... |
DB08895 | DB08901 | 976 | 1,468 | [
"DDInter1825",
"DDInter1492"
] | Tofacitinib | Ponatinib | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
976,
25,
1468
]
],
[
[
976,
64,
478
],
[
478,
24,
1468
]
],
[
[
976,
63,
1215
],
[
1215,
23,
1468
]
],
[
[
976,
62,
307
],
[
307,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} ma... | Tofacitinib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cau... |
DB01174 | DB01229 | 697 | 973 | [
"DDInter1442",
"DDInter1378"
] | Phenobarbital | Paclitaxel (protein-bound) | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
697,
24,
973
]
],
[
[
697,
24,
310
],
[
310,
63,
973
]
],
[
[
697,
6,
7524
],
[
7524,
45,
973
]
],
[
[
697,
21,
31047
],
[
31047,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Ph... |
DB00176 | DB00619 | 529 | 1,419 | [
"DDInter770",
"DDInter909"
] | Fluvoxamine | Imatinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
529,
24,
1419
]
],
[
[
529,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
529,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
529,
25,
222
],
[
222,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluvoxamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Fluvoxamine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Fluvoxamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may... |
DB08865 | DB15093 | 1,593 | 1,654 | [
"DDInter448",
"DDInter1698"
] | Crizotinib | Somapacitan | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1593,
24,
1654
]
],
[
[
1593,
63,
10
],
[
10,
24,
1654
]
],
[
[
1593,
25,
1135
],
[
1135,
24,
1654
]
],
[
[
1593,
64,
1010
],
[
1010,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Crizotinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a moder... |
DB00206 | DB01284 | 1,245 | 1,042 | [
"DDInter1582",
"DDInter1782"
] | Reserpine | Tetracosactide | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
1245,
24,
1042
]
],
[
[
1245,
24,
1148
],
[
1148,
23,
1042
]
],
[
[
1245,
24,
1144
],
[
1144,
24,
1042
]
],
[
[
1245,
24,
1450
],
[
14... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and N... |
DB00341 | DB01618 | 1,242 | 776 | [
"DDInter343",
"DDInter1239"
] | Cetirizine | Molindone | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
1242,
24,
776
]
],
[
[
1242,
21,
28800
],
[
28800,
60,
776
]
],
[
[
1242,
24,
100
],
[
100,
24,
776
]
],
[
[
1242,
24,
407
],
[
407,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyskinesia"
],
[
"Dyskinesia",
"{u} (Side Effect) is cau... | Cetirizine (Compound) causes Dyskinesia (Side Effect) and Dyskinesia (Side Effect) is caused by Molindone (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01037 | DB06209 | 1,161 | 256 | [
"DDInter1653",
"DDInter1508"
] | Selegiline | Prasugrel | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Minor | 0 | [
[
[
1161,
23,
256
]
],
[
[
1161,
6,
10215
],
[
10215,
45,
256
]
],
[
[
1161,
21,
28681
],
[
28681,
60,
256
]
],
[
[
1161,
25,
593
],
[
593... | [
[
[
"Selegiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Selegiline",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Selegiline (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Selegiline (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Selegiline may lead to a major life threatening interaction when taken with Bupropion and Buprop... |
DB00390 | DB11581 | 1,252 | 1,456 | [
"DDInter554",
"DDInter1926"
] | Digoxin | Venetoclax | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
1252,
24,
1456
]
],
[
[
1252,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
1252,
23,
752
],
[
752,
24,
1456
]
],
[
[
1252,
24,
1362
],
[
1362... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"B... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Digoxin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may... |
DB04845 | DB08901 | 309 | 1,468 | [
"DDInter1001",
"DDInter1492"
] | Ixabepilone | Ponatinib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
309,
24,
1468
]
],
[
[
309,
24,
478
],
[
478,
24,
1468
]
],
[
[
309,
6,
8374
],
[
8374,
45,
1468
]
],
[
[
309,
21,
29425
],
[
29425,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ixabepilone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound)
Ixabepilone (Compoun... |
DB00598 | DB01143 | 1,523 | 923 | [
"DDInter1013",
"DDInter65"
] | Labetalol | Amifostine | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
1523,
24,
923
]
],
[
[
1523,
21,
28642
],
[
28642,
60,
923
]
],
[
[
1523,
24,
714
],
[
714,
24,
923
]
],
[
[
1523,
40,
954
],
[
954,
... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} ... | Labetalol (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Labetalol ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.